ArticleNPJ precision oncology2026
Spatial transcriptomics of en bloc transurethral resection of bladder tumor specimens defines an invasive-front gene expression signature.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bladder cancer is classified by depth of invasion into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). Because some NMIBC cases progress to MIBC, it is important to elucidate the mechanisms of invasion. Spatial transcriptomics is a powerful tool for characterizing the tumor microenvironment. We applied Visium to seven high-grade NMIBC tumors using en bloc transurethral resection of bladder tumor (ERBT) specimens that preserve three-dimensional tumor architecture. Malignant regions were divided into the tumor-upper and tumor-boundary regions, and seven cases were further stratified by pathological subgroup based on the muscularis mucosae. We identified 15 genes with boundary-enriched expression in the higher-risk subgroup. These genes were enriched for epithelial-mesenchymal transition and myogenesis features. To assess the generalizability of this finding, we analyzed public bulk RNA-seq datasets and found that higher expression of the 15-gene signature was associated with worse overall survival, suggesting potential utility for prognostic stratification and therapeutic decision-making.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.